CD20 on B Cells, Blood
Use
This test is useful for evaluating patients with a suspected CD19 deficiency (humoral immunodeficiency) and confirming the complete absence of B cells in suspected primary humoral immunodeficiencies using both CD19 and CD20 markers. It is also used for assessing therapeutic B-cell depletion quantitatively in various clinical contexts, including malignancies, autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus, and in treating or preventing acute humoral rejection in positive crossmatch renal transplant recipients.
Special Instructions
This test should not be used to assess whether B cells express CD20 for initiating therapeutic monoclonal anti-CD20 antibody therapy for hematologic malignancies or in other clinical contexts. Do not order the detailed analysis of B cell subsets for quantitatively measuring total CD19 or CD20+ B cells.
Limitations
CD20 deficiency or the use of anti-CD20 antibodies may prevent the detection of CD20 on B cells, hindering accurate assessment of B-cell presence or levels in conditions requiring this evaluation. This test is also not suitable for cases involving the evaluation of malignant or nonmalignant B-cell presence, where an alternative test like CEE20 should be considered.
New York Approved
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
LOINC Codes
- 100994-3
- 8117-4
- 8116-6
- 8119-0
- 9558-8
- 27071-0
- 48767-8
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3 mL
Minimum Volume
1 mL
Container
Lavender top (EDTA)
Collection Instructions
Send whole blood specimen in original tube. Do not aliquot.
Causes for Rejection
Gross hemolysis, gross lipemia, secondary aliquot tube.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 4 days |